Drug Profile
RBM 001
Alternative Names: RBM-001Latest Information Update: 30 Jun 2023
Price :
$50
*
At a glance
- Originator Ribomic
- Class Anti-inflammatories; Nucleotide aptamers
- Mechanism of Action MDK protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Discontinued Bone disorders; Encephalomyelitis; Inflammation
Most Recent Events
- 23 Jun 2023 Discontinued - Preclinical for Bone disorders in Japan (Parenteral) (Ribomic pipeline, June 2023)
- 23 Jun 2023 Discontinued - Preclinical for Encephalomyelitis in Japan (Parenteral) (Ribomic pipeline, June 2023)
- 15 Jul 2021 Discontinued - Preclinical for Inflammation in Japan (Parenteral) (Ribomic pipeline, July 2021)